ACRV Stock — Acrivon Therapeutics Inc.: Cash, EV, Pipeline

Share price

$1.85

Market cap

$79.3M

Cash

$90.0M

Enterprise value

-$10.7M

Balance sheet

Cash	$90.0M
Debt	$0.0M
Net cash	$90.0M
Enterprise value	-$10.7M
Basic shares	42.8M shares
Fully diluted shares	58.3M shares
Fully diluted market cap	$107.8M
Cash per share	$2.10

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading ACRV daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Sep 23 - Nov 4	ACR-2316	Phase 1	Specific Advanced Solid Tumors	—
Jul 11 - Aug 22	ACR-368	Phase 2	Endometrial Adenocarcinoma	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

ACR-368

Phase 2 · Active Modality: small molecule inhibitor

Aliases prexasertib

Target CHK1/2

Partnerships In-licensed from Eli Lilly and Company; OncoSignature companion test performed by Akoya (CLIA lab) under agreement

Indications

Endometrial cancer (EC) (Phase 2)
Squamous cell carcinoma of head and neck (SCCHN) (Phase 2)

Catalysts

— second half of 2026

Status note Phase 2b registrational-intent study; lead program. SCCHN indication evaluated in an investigator-initiated trial (IIT). Received FDA Fast Track designation for ACR-368 monotherapy based on OncoSignature-predicted sensitivity. Earlier Lilly-sponsored Phase 2 included platinum-resistant ovarian cohorts, but the current program focuses on EC.

ACR-2316

Phase 2 · Active

Target WEE1/PKMYT1

Indications

Small cell lung cancer (SCLC) (Phase 2)
Squamous non-small cell lung cancer (sqNSCLC) (Phase 2)
Adenocarcinoma non-small cell lung cancer (adNSCLC) (Phase 2)

Status note Filing describes a Phase 1/2 study (dose escalation complete, two weekly dosing regimens established) now in the dose-expansion stage in AP3-identified, molecularly defined tumors. Second clinical-stage asset.

CDK11 program

Preclinical · Active

Target CDK11

Status note Internally discovered development candidates toward planned IND filing; discovered via AP3 co-crystallography platform. IND-enabling studies being initiated.

Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	ACR-368
Lead indication	Endometrial Adenocarcinoma
Lead phase	Phase 2
Active trials	2
Collaborator trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05548296	Phase 2	Recruiting	Sponsor	Acrivon Therapeutics	—	Endometrial Adenocarcinoma	—
NCT06667141	Phase 1	Recruiting	Sponsor	Acrivon Therapeutics	—	Specific Advanced Solid Tumors	—
NCT06597565	Phase 2	Recruiting	Collaborator	H. Lee Moffitt Cancer Center and Research Institute	—	Head and Neck Squamous Cell Carcinoma	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 3 active trials for Acrivon Therapeutics on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

ACRV — Acrivon Therapeutics Inc.